21160 WEBCAST: Challenges and Opportunities in the Transplant Patient: Focus on Improving Care for CMV Infection
This activity can be accessed using the following URL:
- Medical Oncologists
- Investigators who treat or are interested in the treatment of patients with hematologic malignancies
- Other allied healthcare professionals (Nurse Practitioners, Physician Assistants, and Nurses involved in the treatment and management of patients with hematologic malignancies
• Updates on novel induction and integration of targeted agents
• Antibody strategies in HCT-eligible AML: from conditioning to future applications
• Insights on maintenance strategies in HCT recipients
This activity is supported by an educational grant from Actinium Pharmaceuticals, Astellas Pharma Global Development, Inc., Bristol Myers Squibb, and Gilead Sciences, Inc.
As organizations accredited by the ACCME, the Medical College of Wisconsin and Medscape, LLC, require everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
Camille Nelson Kotton, MD
Transplant and Immunocompromised Host Infectious Diseases
Massachusetts General Hospital
Disclosure: Camille Nelson Kotton, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Hookipa; Merck; Roche Diagnostics; Takeda
Served as a speaker or a member of a speakers bureau for: Roche Diagnostics
Francisco M. Marty, MD
Associate Professor of Medicine
Harvard Medical School
Brigham and Women's Hospital
Disclosure: Francisco M. Marty, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AlloVir; Amplyx; Avir; F2G; Gilead; Janssen; Kyorin; Merck; Regeneron; ReViral; Symbio; United Medical
Received grants for clinical research from: Amplyx; Ansun; Chimerix; Cidara; F2G; Gilead; Merck; Regeneron; Scynexis; Takeda; WHISCON
Genovefa Papanicolaou, MD
Infectious Disease Service
Memorial Sloan Kettering Cancer Center
Weill Cornell Medicine
New York, New York
Disclosure: Genovefa A. Papanicolaou, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ADMA Biologics; Astellas; Cidara; Merck; Octapharma; Partner Therapeutics; Siemens; Shionogi
Received grants for clinical research from: Astellas; Merck & Co.; Takeda
Other: Allovir; Amplyz; DSMC; EAC Octapharma
Maria B. Uravich, BSc, ELS
Senior Medical Education Director, Medscape, LLC
Disclosure: Maria B. Uravich, BSc, ELS, has disclosed no relevant financial relationships.
CME, CE Reviewer/Nurse Planner
Stephanie Corder, ND, RN, CHCP
Associate Director, Accreditation and Compliance, Medscape, LLC
Disclosure: Stephanie Corder, ND, RN, CHCP, has disclosed no relevant financial relationships.
Bronwen E. Shaw, MD, PhD
Disclosure: Bronwen E. Shaw, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Orca bio; Therakos
Received honorarium from: Therakos
Additional Disclosure: CIBMTR receives financial support from the government, foundations and industry entities listed below to support broad research and educational missions. These funding sources are disclosed for transparency. Scientific and administrative review processes prevent direct influence of the funding sources to the CIBMTR scientific research agenda and individual research products and findings.
Medscape, LLC staff have disclosed that they have no relevant financial relationships.
This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.
This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc., and Merk & co., Inc.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Medical College of Wisconsin and PER, Physician Education Resource, LLC. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.